Vulpes vulpes

@sls0
 

29 janvier

S’il y en a qui aime discuter pendant des heures sur agoravox.tv, d’autres préfèrent vivre hors du virtuel dans la vraie vie.

Un commentaire ce n’est pas pour avoir raison, celui qui a la plus grosse. C’est un message qui doit avoir un impact. [...]

Voilà pourquoi je ne suis pas un assidu ici. Je regarde de temps en temps, s’il faut j’intervient.

Le "s’il faut" ce n’est pas dans le cadre égotique d’avoir raison ou de m’étaler à coups de commentaires, c’est quand le falacieux est trop visible. Prouver le faux c’est aussi chercher les preuves, ça prend du temps, temps que l’on a pas pour s’étaler dans les commentaires.

@CoolDude
 
Merci pour la vidéo !
 
Quel mépris pour les gens ordinaires !? C’est incroyable !!
 
Le documentaire peut être regardé en intégralité ici.
 

Merci pour l’article !

C’est intéressant !

@PFIZE®baba

Un petit mot bubu sur le purpura thrombopénique immunologique ? 

l’analyse d’un cas de purpura thrombopénique immunologique avec rechallenge positif, même s’il avait été constaté avant normalisation de la formule plaquettaire, avait déjà été considéré comme un élément fort en faveur d’une possible responsabilité du vaccin et transmis à l’échelon européen où un signal similaire était en cours d’investigation.

Enquête de pharmacovigilance du vaccin Pfizer – BioNTech Comirnaty, Rapport n°14 : période du 16 avril 2021 au 29 avril 2021, CRPV de Bordeaux, CRPV de Marseille, p. 23

Dr. Gregory Michael, a 56-year-old obstetrician and gynecologist in Miami Beach, received the vaccine at Mount Sinai Medical Center on Dec. 18 and died 16 days later from a brain hemorrhage, his wife, Heidi Neckelmann, wrote in a Facebook post.

Shortly after receiving the vaccine, Dr. Michael developed an extremely serious form of a condition known as acute immune thrombocytopenia, which prevented his blood from clotting properly.

Doctor’s Death After Covid Vaccine Is Being Investigated

https://www.nytimes.com/2021/01/12/health/covid-vaccine-death.html

One day after receiving her first dose of Moderna’s Covid vaccine, Luz Legaspi, 72, woke up with bruises on her arms and legs, and blisters that bled inside her mouth. She was hospitalized in New York City that day, Jan. 19, with a severe case of immune thrombocytopenia — a lack of platelets, a blood component essential for clotting.

The same condition led to the death in January of Dr. Gregory Michael, 56, an obstetrician in Miami Beach whose symptoms appeared three days after he received the Pfizer-BioNTech vaccine. Treatments failed to restore his platelets, and after two weeks in the hospital he died from a brain hemorrhage.

It is not known whether this blood disorder is related to the Covid vaccines. More than 31 million people in the United States have received at least one dose, and 36 similar cases had been reported to the government’s Vaccine Adverse Event Reporting System, VAERS, by the end of January. The cases involved either the Pfizer-BioNTech or Moderna vaccine, the only two authorized so far for emergency use in the United States.

A Few Covid Vaccine Recipients Developed a Rare Blood Disorder

https://www.nytimes.com/2021/02/08/health/immune-thrombocytopenia-covid-vaccine-blood.html

@PFIZE®baba

Un petit mot bubu sur ces chiffres qui viennent du Lancet  ? 

COVID-19 vaccine efficacy and effectiveness—the elephant (not) in the room 

Piero Olliaro, Els Torreele, Michel Vaillant

The Lancet Microbe, Published : April 20, 2021 DOI :https://doi.org/10.1016/S2666-5247(21)00069-0

ARRs [the absolute risk reduction] tend to be ignored because they give a much less impressive effect size than RRRs : […] 0.84% for the Pfizer–BioNTech vaccine.

ARR is also used to derive an estimate of vaccine effectiveness, which is the number needed to vaccinate (NNV) to prevent one more case of COVID-19 as 1/ARR. NNVs bring a different perspective : 76 for the Moderna–NIH, 78 for the AstraZeneca–Oxford, 80 for the Gamaleya, 84 for the J&J, and 117 for the Pfizer–BioNTech vaccines. The explanation lies in the combination of vaccine efficacy and different background risks of COVID-19 across studies : 0·9% for the Pfizer–BioNTech.

The only reported indication of vaccine effectiveness is the Israeli mass vaccination campaign using the Pfizer–BioNTech product. Although the design and methodology are radically different from the randomised trial,Dagan and colleagues report an RRR of 94%, which is essentially the same as the RRR of the phase 3 trial (95%) but with an ARR of 0·46%, which translates into an NNV of 217 (when the ARR was 0·84% and the NNV was 119 in the phase 3 trial). This means in a real-life setting, 1.8 times more subjects might need to be vaccinated to prevent one more case of COVID-19 than predicted in the corresponding clinical trial.

These considerations on efficacy and effectiveness are based on studies measuring prevention of mild to moderate COVID-19 infection ; they were not designed to conclude on prevention of hospitalisation, severe disease, or death, or on prevention of infection and transmission potential. Assessing the suitability of vaccines must consider all indicators, and involve safety, deployability, availability, and costs.